Stockreport

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Ocugen, Inc.  (OCGN) 
PDF Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trialActively dosing patients in OCU400 [Read more]